Zortress .75 mg/1 (Everolimus TABLET) .75 mg/1

Everolimus, the active ingredient in Zortress, works by inhibiting the mammalian target of rapamycin (mTOR) pathway. This pathway plays a crucial role in cell proliferation, growth, and survival. By binding to the FKBP-12 protein, everolimus forms a complex that inhibits mTOR, thereby suppressing T-cell proliferation and cytokine production, which helps prevent organ rejection.

The usual dose of Zortress is determined by a healthcare professional based on the patient's specific needs and medical history. For kidney transplant patients, an initial dose of 0.75 mg orally twice daily is recommended in combination with reduced doses of cyclosporine. For liver transplant patients, an initial dose of 1 mg orally twice daily is recommended in combination with reduced doses of tacrolimus. Dose adjustments may be necessary based on blood concentrations and individual response.

Zortress should be avoided during pregnancy due to potential risks to the fetus. It is also not recommended during breastfeeding due to potential risks to the infant. Patients should discuss their reproductive health and contraceptive options with their healthcare provider before starting Zortress.

To order Zortress from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then reply with pricing, availability, shipping, and the import paperwork.

Zortress is an mTOR inhibitor, which differs from other immunosuppressants like calcineurin inhibitors (e.g., tacrolimus) and corticosteroids. It is specifically used to prevent organ rejection in transplant patients and is often used in combination with other immunosuppressants. The choice of immunosuppressant depends on the patient's specific needs and medical history, as determined by a healthcare professional.

Zortress should be stored below 25°C, keeping it in the original pack and protecting it from moisture. It is important to follow the storage instructions provided with the medication to ensure its effectiveness and safety. Patients should also handle the medication carefully and follow their healthcare provider's instructions for administration.

Zortress is administered orally in the form of tablets. The dosage and administration schedule are determined by a healthcare professional based on the patient's specific needs and medical history. It is important to follow the prescribed dosage and administration instructions to ensure the medication's effectiveness and safety.

The most serious risks associated with Zortress include an increased risk of infections, wound healing problems, lung problems, kidney problems, and blood clots. Patients should be monitored regularly by their healthcare provider and report any unusual symptoms or side effects immediately. It is important to follow the healthcare provider's instructions for monitoring and managing these risks.

Zortress should not be used by patients who are allergic to everolimus or any of the other ingredients in the medication. It should also be avoided during pregnancy and breastfeeding due to potential risks to the fetus and infant. Patients with certain medical conditions, such as severe liver or kidney problems, may also need to avoid Zortress. It is important to discuss any medical conditions and allergies with a healthcare provider before starting Zortress.